TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

BostonGene Unveils CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling, and Spatial Proteomics Solutions

Saturday, June 03, 2023

BostonGene has made an exciting announcement today regarding the launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling, and Spatial Proteomics solutions. These cutting-edge offerings integrate multiple AI-based molecular and immune profiling techniques to provide a comprehensive understanding of a patient's disease. By analyzing tumor, microenvironment, and host immunity, BostonGene's solutions aim to support and improve the efficacy of clinical trials and research and development efforts. They will enable the precise characterization of clinical trial populations, evaluation of treatment safety and effectiveness, monitoring of side effects, and identification of appropriate patient populations for a wide range of therapies.

BostonGene has introduced a range of cloud-based solutions, bioinformatics capabilities, analytical tools, and advanced next-generation sequencing. These powerful offerings provide an integrated platform for analyzing both the patient and their tumor, generating data-driven results that have the potential to revolutionize patient care and disrupt traditional approaches to precision medicine.

According to Dr. Mark Poznansky, an academic research collaborator with BostonGene, Director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School, the development of innovative therapies relies on the support of emerging technologies. He highlights the importance of an integrated approach that enables patients to gain a deeper understanding of their disease and make informed decisions about their treatment.

BostonGene's comprehensive suite of tools and technologies empowers healthcare providers to deliver personalized and informed care to patients. By leveraging cloud-based solutions, bioinformatics capabilities, analytical tools, and advanced sequencing, BostonGene is driving advancements in precision medicine and improving patient outcomes.

BostonGene has introduced a range of innovative solutions that offer valuable insights for clinicians and researchers. Their Spatial Proteomics solution utilizes a multiplex immunofluorescence (MxIF) assay to provide a comprehensive overview of tumor cells, immune cell infiltration, stromal and vascular components, and tissue architecture. By combining imaging biomarker detection with a virtual H&E slide, BostonGene enables the creation of a multiparametric tumor architecture.

The Immunoprofiling solution by BostonGene allows for the identification of surrogate biomarkers using a single blood sample. This approach is beneficial for clinical trial patient selection, monitoring disease progression and treatment response, guiding immunotherapy treatment decisions, and identifying immune-related patient conditions.

BostonGene's Liquid Biopsy assay is designed for high-sensitivity detection of clinically relevant gene alterations. It covers a wide range of pan-cancer biomarkers and analyzes 216 genes, including complete exonic coverage of 200 genes. With proprietary error reduction algorithms and hematopoietic mutation filtration, the Liquid Biopsy assay provides accurate results for disease progression prediction, treatment response monitoring, and personalized treatment selection.

Dr. Nathan Fowler, Chief Medical Officer at BostonGene, emphasizes that their solutions offer evidence-based recommendations to guide clinical decision-making. By leveraging big data and comprehensive molecular profiling, BostonGene's tests provide a deep understanding of a patient's tumor drivers, immune microenvironment properties, actionable mutations, biomarkers for therapy response, and personalized treatment recommendations.
Through their advanced solutions, BostonGene aims to transform patient care by providing clinicians and researchers with valuable insights and personalized treatment options.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit